Raphi Levy Sells 2,127 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,127 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $13.02, for a total value of $27,693.54. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at $1,174,143.60. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Up 1.1%

Shares of NASDAQ:DRTS traded up $0.14 during trading on Thursday, reaching $12.78. 475,428 shares of the stock were exchanged, compared to its average volume of 577,559. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a 1-year low of $2.87 and a 1-year high of $13.06. The stock has a fifty day moving average of $9.64 and a two-hundred day moving average of $7.79. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -19.08 and a beta of 1.16.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Research analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Piper Sandler boosted their price objective on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Finally, LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.60.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently added to or reduced their stakes in DRTS. Mariner LLC increased its stake in Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after buying an additional 1,915 shares during the last quarter. Trifecta Capital Advisors LLC purchased a new position in shares of Alpha Tau Medical in the 4th quarter worth approximately $48,000. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the third quarter valued at approximately $62,000. Wells Fargo & Company MN grew its holdings in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical during the first quarter valued at approximately $132,000. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.